Apogossypol

CAS No. 66389-74-0

Apogossypol( +)-Apogossypol | NSC 736630 )

Catalog No. M15530 CAS No. 66389-74-0

Apogossypol (NSC 736630) is a Bcl-2 family antagonist that binds to Bcl-XL, Bcl-2 and Bcl-xL with IC50 of 2.6, 2.8 and 3.69 uM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1053 Get Quote
50MG 2142 Get Quote
100MG 2790 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Apogossypol
  • Note
    Research use only, not for human use.
  • Brief Description
    Apogossypol (NSC 736630) is a Bcl-2 family antagonist that binds to Bcl-XL, Bcl-2 and Bcl-xL with IC50 of 2.6, 2.8 and 3.69 uM, respectively.
  • Description
    Apogossypol (NSC 736630) is a Bcl-2 family antagonist that binds to Bcl-XL, Bcl-2 and Bcl-xL with IC50 of 2.6, 2.8 and 3.69 uM, respectively; induces apoptosis of tumor cell lines, inhibits the growth and proliferation of prostate cancer cells by downregulating Bcl?2 protein expression and activating caspase?3 and ?8; displays superior activity to gossypol in terms of reducing splenomegaly and reducing B-cell counts in spleens of Bcl-2-transgenic mice.
  • In Vitro
    In agreement with NMR binding and fluorescence polarization assays (FPAs) data, (+)-Apogossypol displays potent binding affinity to Bcl-xL with Kd values of 1.7 μM.To investigate the inhibitory effects of (+)-Apogossypol and Gossypol on LNCaP cell survival, the MTT assay is performed. The results demonstrate that (+)-Apogossypol inhibits the proliferation of LNCaP cells in a time- and dose-dependent manner, in a similar way with Gossypol. The concentration for 50% inhibition (IC50) on LNCaP cells within ~72 h is 9.57 μM, while the IC50 of Gossypol on LNCaP cells is 10.35 μM.
  • In Vivo
    Due to its modified structure, (+)-Apogossypol is expected to exhibit lower toxicity while maintaining the significant anti-growth and anti-tumor activities in vitro, similar to those of Gossypol. The anti-cancer effect of (+)-Apogossypol is evaluated in mice bearing subcutaneous LNCaP cell xenografts. The tumor growth is monitored and measured by a caliper and balance. The survival rate of the mice is notably improved by (+)-Apogossypol. Of note, the tumor sizes are also markedly decreased by (+)-Apogossypol treatment (P<0.01).
  • Synonyms
    +)-Apogossypol | NSC 736630
  • Pathway
    Angiogenesis
  • Target
    Bcl-2
  • Recptor
    Bcl-2
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    66389-74-0
  • Formula Weight
    462.53
  • Molecular Formula
    C28H30O6
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    CC1=CC2=C(C(=C(C=C2C(=C1C3=C(C4=CC(=C(C(=C4C=C3C)C(C)C)O)O)O)O)O)O)C(C)C
  • Chemical Name
    [2,2'-Binaphthalene]-1,1',6,6',7,7'-hexol, 3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (2S)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Becattini B, et al. Chem Biol. 2004 Mar;11(3):389-95. 2. Wei J, et al. Mol Cancer Ther. 2009 Apr;8(4):904-13. 3. Kitada S, et al. Blood. 2008 Mar 15;111(6):3211-9. 4. Zhan W, et al. Mol Med Rep. 2015 Jun;11(6):4142-8.
molnova catalog
related products
  • Isoverticine

    Isoverticine exhibits significant antitussive, expectorant and anti-inflammatory activities, it also displays significant cytotoxicity.

  • UMI-77

    A potent and selective Mcl-1 inhibitor with Ki of 0.49 uM; displays >10 fold selectivity against Bcl-w, Bfl-1, Bcl-xL and Bcl-2.

  • BXI-72

    BXI-72 (NSC334072, Hoechst 33342) is a potent, selective small molecule Bcl-XL inhibitor that targets the BH3 domain of Bcl-XL (Kd=0.9 nM).